Friday, July 10, 2026

pharma · Hepatitis C Virus Infection · Chronic Hepatitis B

Gilead Sciences Ireland

Gilead Sciences is a pharma organization headquartered in Foster City, USA. Primary therapeutic focus areas include Hepatitis C Virus Infection, Chronic Hepatitis B, HIV-1-infection, HCV Infection, Crohn's Disease. NovaP

333 Lakeside Drive, Foster City, CA 94404, US HQ
1987 Founded
14,602 Employees
EMA registrant Type
Company details
Status
Public
HQ
333 Lakeside Drive, Foster City, CA 94404, US
Founded
1987
Employees
14,602
Programs
26
Drugs
17
Patents
0
Clinical program

Sacituzumab Govitecan-hziy

Phase 3 · small molecule · Triple Negative Breast Cancer

Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer is a Phase 3 program (small_molecule) at Gilead Sciences Ireland UC with 1 ClinicalTrials.gov record(s).

← All Gilead Sciences Ireland UC projects Phase 3 small molecule active

Internal code GS-US-592-6173

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Gilead Sciences Ireland UC
Phase
Phase 3
Modality
small_molecule
Indication
Triple Negative Breast Cancer
Status
active
Trials
1